(M12) was observed yet significant improvement in disease activity was found in both groups.Hence,results from the 2 groups were combined to ascertain if achieving sustained DAS remission can prevent AS progression.The disease activity improved significantly [DAS: 4.8 (4.2,5.6) at baseline (BL) vs 2.38 (1.6,3.0) at M12, p<0.001]. 57% patients achieved DAS remission at M12 and 36% patients achieved DAS remission over 3 consecutive visits (sustained remission). No significant differences were found in disease activity, cardiovascular risk factors (CRF) and baPWV at BL between groups who can (CA) or cannot achieve (NA) sustained remission. At M12, no significant differences in CRF and baPWV were found between groups.However, the change in baPWV was significantly different between CA and NA group [-65.5 (-147.25, 44.0) cm/s vs 39 (-65.25, 124.75) cm/s, p=0.005]. The differences remained significant in the %change of baPWV [-4.4 (-9.67-2.84)% vs 2.51 (-4.34-10.28)%, p=0.006].I n univariate analysis,assocation of change in baPWV and potential predictors included BL baPWV, blood pressure (systolic & diastolic) and sustained DAS remission was found.By multivariate analysis,achieving sustained DAS remission was an independent predictor for baPWV reduction. Background: Musculoskeletal disorders (MSDs) are the leading cause of temporary and permanent work related disability across Europe, yet many people are able to remain at work. Objectives: To explore perceived facilitators and barriers to staying at work amongst people experiencing MSD. Methods: Semi-structured interviews conducted with 19 individuals who had attended musculoskeletal assessment clinics in three Irish hospitals within the preceding year with a confirmed diagnosis of non-inflammatory musculoskeletal disorder. Participants were only included if they had been in paid employment continuously for at least six of the previous 12 months. The interviews were audio-recorded and transcribed. Data were analysed using thematic analysis.
(M12) was observed yet significant improvement in disease activity was found in both groups.Hence,results from the 2 groups were combined to ascertain if achieving sustained DAS remission can prevent AS progression.The disease activity improved significantly [DAS: 4.8 (4.2, 5.6 ) at baseline (BL) vs 2.38 (1.6,3.0) at M12, p<0.001]. 57% patients achieved DAS remission at M12 and 36% patients achieved DAS remission over 3 consecutive visits (sustained remission). No significant differences were found in disease activity, cardiovascular risk factors (CRF) and baPWV at BL between groups who can (CA) or cannot achieve (NA) sustained remission. At M12, no significant differences in CRF and baPWV were found between groups.However, the change in baPWV was significantly different between CA and NA group [-65.5 (-147.25, 44 .0) cm/s vs 39 (-65.25, 124 .75) cm/s, p=0.005]. The differences remained significant in the %change of baPWV [-4.4 (-9 .67-2.84)% vs 2.51 (-4.34-10.28)%, p=0.006] .I n univariate analysis,assocation of change in baPWV and potential predictors included BL baPWV, blood pressure (systolic & diastolic) and sustained DAS remission was found.By multivariate analysis,achieving sustained DAS remission was an independent predictor for baPWV reduction. Background: Musculoskeletal disorders (MSDs) are the leading cause of temporary and permanent work related disability across Europe, yet many people are able to remain at work. Objectives: To explore perceived facilitators and barriers to staying at work amongst people experiencing MSD. Methods: Semi-structured interviews conducted with 19 individuals who had attended musculoskeletal assessment clinics in three Irish hospitals within the preceding year with a confirmed diagnosis of non-inflammatory musculoskeletal disorder. Participants were only included if they had been in paid employment continuously for at least six of the previous 12 months. The interviews were audio-recorded and transcribed. Data were analysed using thematic analysis. Results: Participants ranged in age from 21 to 50 years, most were female (n=16). Fifteen participants were continuing to work, while experiencing pain and some functional limitations. Job control emerged as a key factor in continued work participation, specifically, being able to organise workload and make modifications to work practices enabled participants to maintain an acceptable level of work performance. The value of work, both personal and financial, motivated people to continue to work. While some co-workers and supervisors were considered to be helpful, interviewees were concerned that they could lose their job if they asked for assistance or took time off work. Fatigue had a considerable impact on life outside of work, with interviewees reporting effects on family life and reduced participation in social activities. Conclusions: While continuing to work was beneficial, negative spillover effects on life outside of work were commonly reported. Workers with MSD may benefit from interventions that focus on coping with pain and fatigue management, as well as those that raise awareness amongst employers. Background: Ankylosing spondylitis (AS) is a major chronic rheumatic disease that predominantly affects axial joints, determining a rigid spine from the occiput to the sacrum. The disease can lead to permanent spinal deformity and postural disorder during the later stages. Changes in axial mobility may lead to impaired postural control, with altered postural control being associated with increased fall risk and lower quality of life. The population with AS has been rarely studied regarding postural control, both dynamic and static. Objectives: The aim was to investigate the relationship between spinal mobility and static and dynamic balance of patients with mild to moderate AS. Methods: The study included 137 (74 male and 63 female) patients with a mean age of 51.19±10.72 (20-78) years who were diagnosed with AS according to the modified New York criteria. Patients were divided into two groups as tragus to the wall distance (TWD) <15 cm (Group I = mild AS, n=51) and TWD ≥15 (Group II = moderate AS, n=84). The mean duration of disease in Group I was 17.83±11.3 (1 -50) years and the mean duration of disease in Group II was 20.78±9.67 (2 -43) years. Spinal mobility measurements [TWD, cervical rotation (CR), modified Schober test (MST), lumbar lateral flexion (LLF), intermalleolar distance (IMM), thoracic expansion (TE) tests] were compared with static and dynamic balance tests in the groups. Static balance was assessed with one-foot standing with eyes open and closed. Dynamic balance was assessed with timed up and go test and Berg balance scale. Results: A statistically significant difference was found between spinal mobility measurements and Berg balance scale scores between the groups. Spinal mobility values of Group II were worse than Group I (p<0.05). Berg balance scale scores were better in Group I than Group II (p=0.028). No statistically significant difference was found between the two groups in terms of static balance and timed up and go test (p>0.05). There was a weak and significant correlation between spinal mobility measurements [CR, MST, LLF, IMM, and TE] and static and dynamic balance in the positive direction (r=0.177-0.284, p<0.05). There was no significant correlation between TWD and static and dynamic balance (p>0.05).
Conclusions

Conclusions:
In patients with AS, as the severity of the disease progresses, spinal mobility and dynamic balance worsen; however, the static balance does not change. These changes in the posture and balance can negatively affect patients' participation levels in daily life and increase their risk of falling. For this reason, we think that detailed evaluation of balance, balance training and fall preventing approaches should be included in the rehabilitation programs for the patients with AS.
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